We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Beijing Genome Institute and PentaBase Strengthen their Collaboration

Read time: Less than a minute

Chinese Beijing Genome Institute, BGI, has announced that it has increased its collaboration with PentaBase, Denmark. Following a successful first benchmark of PentaBase’s technologies against competing technologies, BGI (together with Danish BGI partner SD Genomics) and PentaBase have now strengthened their collaboration with the aim to co-develop outstanding kits for the detection of important clinical biomarkers. The kits will be based on Real-Time PCR.

With the general trend pointing towards Personalized Medicine, development of robust, sensitive and specific genetic diagnostics is essential. BGI, SD Genomics and PentaBase want to launch a range of ground breaking diagnostic assays. It is a perfect fit between two parties with complementary knowledge and technology. "We have magnificent perspectives in creating a win-win situation,” says Ulf B. Christensen, CEO, PentaBase.